Research Article
Salivary Fractalkine Differentiating Periodontitis from Periodontally Healthy Subjects
Table 2
Statistical analysis of the concentration of salivary biomarkers among all groups.
| | Mean | SD | Minimum | Maximum | p-Value |
| CX3CL1 (ng/mL) | Control | 363.779 | 104.932 | 180.930 | 559.114 | 0.000 | Stage I | 670.440 | 266.821 | 279.888 | 981.535 | Stage II | 389.303 | 52.618 | 315.846 | 547.628 | Stage III | 939.853 | 242.325 | 628.970 | 1,539.470 |
| CX3CR (pg/mL) | Control | 2.634 | 0.958 | 0.573 | 3.775 | 0.000 | Stage I | 7.205 | 3.607 | 2.200 | 15.936 | Stage II | 2.842 | 0.468 | 1.234 | 3.455 | Stage III | 10.413 | 6.128 | 3.940 | 21.210 |
|
|
ANOVA test; CX3CL1: Fractalkine ligand; CX3CR: Fractalkine receptor; SD: standard deviations; Level of significance: significant at . |